cs-7017 + carboplatin + paclitaxel

This is a **combination therapy** consisting of **CS-7017 (efatutazone)**, an oral, selective and potent third-generation peroxisome proliferator-activated receptor gamma (**PPARγ**) agonist of the thiazolidinedione class, plus the chemotherapeutic agents **carboplatin** (a platinum-based DNA-damaging alkylator) and **paclitaxel** (a microtubule-stabilizing agent). CS-7017 (efatutazone) selectively activates PPARγ-mediated transcription, increasing plasma adiponectin and inducing antiproliferative effects through novel mechanisms, such as activation of tumor suppressor gene RhoB and induction of p21 to inhibit cell growth[2][5][4][1]. In clinical studies, CS-7017 has demonstrated preliminary antitumor activity and was well tolerated with expected class-related toxicities including fluid retention and peripheral edema[1][5]. The combination with carboplatin and paclitaxel aims to leverage the cytotoxic effects of the chemotherapeutics alongside PPARγ-mediated pathways for enhanced anti-cancer efficacy, particularly in advanced solid tumors.

Other names

efatutazone + carboplatin + paclitaxel